Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AG-270 + TNG908 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AG-270 | AG270|AG 270 | AG-270 inhibits methionine adenosyltransferase II alpha (MAT2A), to induce cell death of tumor cells reliant on S-Adenosyl-L-methionine (SAM) synthesis (NCI Drug Dictionary). | ||
| TNG908 | TNG-908|TNG 908 | PRMT5 Inhibitor 21 | TNG908 is an MTAP-null selective PRMT5 inhibitor, which potentially decreases proliferation of tumor cells harboring MTAP deletion and inhibits tumor growth (PMID: 39756156). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|